MedPath

A Cognitive Training Tool Based on Life-logging in Mild Cognitive Impairment (ReMemory-MCI)

Not Applicable
Conditions
Mild Cognitive Impairment
Interventions
Behavioral: ReMemory-MCI training
Behavioral: Control intervention
Registration Number
NCT02592187
Lead Sponsor
Consorci Sanitari de Terrassa
Brief Summary

Background: Mild Cognitive Impairment (MCI) is a risk factor for dementia and represents a critical window of opportunity to intervene and alter the trajectory of both cognitive and functional decline. Emerging life-logging technologies has shown a tremendous potential to increase autobiographical memory.

Objective: The main goal of the present study is to develop a Cognitive Training program (CT) for MCI based on life-logging captured by a Wearable Camera (WeC) recording specific autobiographical episodes for stimulating posteriorly episodic memory. The challenge is to create an application to manage this large collection of images, which can be easily retrieved as events by users in a therapeutic context as a multimodal cognitive stimulation. The investigators will conduct a quasi-experimental design with non-equivalent control group, evaluating the effectiveness of the life-logging re-experiencing program immediately and 3-month follow-up period.

Methodology: The design is a pretest, posttest and follow-up design, where 30 adults with MCI were sequentially allocated to one of two conditions: intervention or control group. All subjects wore a lifelogging WeC during two weeks, and subsequently they were generated several videos with the most relevant information of each event. Subjects in the Intervention Group will attend 1-hour individual training sessions 2 times per week for 14 8 weeks. Main outcomes measures will be cognitive, functional, emotional and quality of life measures, as well as biochemical measures (BDNF).

Expected results: The investigators expect the outcomes to provide preliminary evidence that autobiographical experimentation CT programs can positively impact cognitive functioning and may represent an effective strategy to improve memory and functionality in those who begun to experience cognitive decline.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • 65-90 years of age
  • Meet definition criteria for MCI (Petersen, 2004)
  • Be receiving CT at least three month in Day Hospital during three months or more; c) having memory complaint, usually verified by an informant
  • Having memory complaint, usually verified by an informant
  • Memory performance below the mean score for the corresponding age and education group
  • Having normal general cognitive functioning as determined by a Mini-Mental State Examination (MMSE) score > o = 24
  • Having a reliable caregiver who can supervise the patient's daily activities
  • Having Global clinical dementia rating scale score of 0.5
  • Granted written informed consent accepting to participate in the study
Exclusion Criteria
  • Neurological, psychiatric or unstable medical disorders
  • Intellectual deficiency (Premorbid Intellectual Quotient (IQ) -Vocabulary- less 85)
  • Relevant hearing, vision, motor or language deficits
  • Less than 4 years of education e) acquisition of Catalonian or Spanish languages after 15 years old

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental interventionReMemory-MCI trainingReMemory-MCI training
Control interventionControl interventionControl intervention
Primary Outcome Measures
NameTimeMethod
Change in attention after receiving treatmentafter 16 sessions treatment and 3 months

Attention was measured using the Identification Task from the computerized neurocognitive battery Cogstate and the Forward Digit Span from the Wechsler Adult Intelligence Scale, fourth edition (WAIS-IV)

Change in memory after receiving treatmentafter 16 sessions treatment and 3 months

Memory was measured using the Logical Memory Test from the Wechsler Memory Scale, IV version (WMS-IV, Spanish version); the International Shopping List Task and the One Card Learning Task from the computerized neurocognitive battery Cogstate.

Change in executive function, set-shifting after receiving treatmentafter 16 sessions treatment and 3 months

Set-shifting was measured using the Colors Trails Test

Change in executive function, inhibition after receiving treatmentafter 16 sessions treatment and 3 months

Inhibition was measured using the Five Digit Test

Change in working memory after receiving treatmentafter 16 sessions treatment and 3 months

orking memory was measured using the One Back Task from the computerized neurocognitive battery Cogstate and the Backward Digit Span from the Wechsler Adult Intelligence Scale, fourth edition (WAIS-IV).

Change in executive function,verbal fluencyafter 16 sessions treatment and 3 months

erbal Fluency was measured using the Controlled Oral Word Association Test, spanish adaptation, and semantic fluency test using the category Animals

Change in processing speed after receiving treatmentafter 16 sessions treatment and 3 months

Processing speed was measured using the Detection Task from the computerized neurocognitive battery Cogstate battery

Secondary Outcome Measures
NameTimeMethod
Change in neuroplasticiyafter 16 sessions treatment and 3 months

neuroplasticiy was measured using Brain-derived neutrophic factor (BDNF) serum levels

Change in subjective memory complaints after receiving treatmentafter 16 sessions treatment and 3 months

subjective memory complaints was measured using Memory Faiures of EveryDay (MFE) Test

Change in functional capacity after receiving treatmentafter 16 sessions treatment and 3 months

Functional capacity was measured using Functional Assessment Questionnaire (FAQ) and the UCSD Performance-Based Skills Assessment (UPSA).

Change in quality of lifeafter 16 sessions treatment and 3 months

Quality of life was measured using Quality of Life-Alzheimer Disease (QoL-AD)

Change in Caregiver Burdenafter 16 sessions treatment and 3 months

Caregiver Burden was measured using the Zarit Caregiver Burden Scale

Change in patient and caregiver's perception of social supportafter 16 sessions treatment and 3 months

Perception of social support was measured using the Duke-UNC Functional Social Support Questionnaire

Change in Neuropsychiatric symptomsafter 16 sessions treatment and 3 months

Neuropsychiatric symptoms was measured using Neuropsychiatric Inventory Questionnaire (NPI)

Change in depression and anxiety after receiving treatmentafter 16 sessions treatment and 3 months

depression and anxiety were measured using the Hospital Anxiety and Depression Scale (HADS)

Change in patient's self-esteemafter 16 sessions treatment and 3 months

Self-Esteem was measured using the Rosenberg Self-Esteem Scale

© Copyright 2025. All Rights Reserved by MedPath